Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared Holz

Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared HolzПодробнее

The noise for PBMs isn't going to dissipate next year, says Mizuho's Jared HolzПодробнее

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared HolzПодробнее

Election noise may make pharmaceutical stocks 'untenable' for investors, says Mizuho's Jared HolzПодробнее

'Overuse' is causing healthcare insurer headwinds, says Mizuho's Jared HolzПодробнее

It doesn't seem like there's too much momentum for healthcare stocks, says Mizuho's Jared HolzПодробнее

Drugs for obesity are a massive market, says Mizuho's Jared HolzПодробнее

Blocking the Horizon-Amgen deal will be worse for pharma than for biotech, says Mizuho's Jared HolzПодробнее

Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared HolzПодробнее

'Transparency is nonexistent' in U.S. health insurance market, says Mizuho's Jared HolzПодробнее

Mizuho's Jared Holz talks what senate hearings mean for GLP-1 makersПодробнее

Amgen has 'a lot to prove' in the weight-loss drug category, says Mizuho's Jared HolzПодробнее

Mizuho's Jared Holz talks Roche shares surging on GLP-1 dataПодробнее

Pfizer is far behind weight loss drug race despite pill trial, says Mizuho's Jared HolzПодробнее

Eli Lilly's drop after earnings is a buying opportunity, says Mizuho's Jared HolzПодробнее

Mizuho’s Jared Holz breaks down UnitedHealth's Q1 earningsПодробнее

GLP-1 makers could be under pressure in 2025Подробнее

Mizuho's Jared Holz on drug price negotiations: More difficult for industry to get better medicinesПодробнее

Mizuho's Jared Holz on finding opportunities in the biotech spaceПодробнее

Mizuho's Jared Holz on Novo Nordisk: There's not much upside near-termПодробнее